Company Information

CIN
Status
Date of Incorporation
28 November 2013
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2020
Last Annual Meeting
24 August 2020
Paid Up Capital
500,000
Authorised Capital
500,000

Directors

. Sapna
. Sapna
Director/Designated Partner
almost 3 years ago
Nityananda Reddy Kambam
Nityananda Reddy Kambam
Director/Designated Partner
almost 3 years ago
Sivakumaran Meenakshisunderam
Sivakumaran Meenakshisunderam
Director/Designated Partner
over 7 years ago
Madan Mohan Reddy Mettu
Madan Mohan Reddy Mettu
Director
over 10 years ago
Govindarajan Narayanan
Govindarajan Narayanan
Director
about 12 years ago

Patents

Process For Racemization Of Optcally Active Isomer Of 2 Halo 2 (2 Chlorophenyl) Acetic Acid Methyl Ester

ABSTRACT The present invention provide a dynamic kinetic resolution process for Clopidogrel utilizing racemisation of optically active isomer of 2-halo-2-(2-chlorophenyl) acetic acid methyl ester of formula (I). More particularly the present invention relates to S (+) 2-bromo-2-(2-chlorophenyl) acetic acid methyl...

An Improved Process For The Preparation Of Droxidopa And Its Salts

NA

An Improved Process For The Preparation Of Micafungin Sodium

The present invention relates to an improved process for the preparation of Micafungin sodium of a Compound of Formula (I), by treating Micafungin or its base addition salt with sodium salt longer fatty acids.

An Improved Process For The Preparation Of Caspofungin Acetate And Its Intermediates

The present invention relates to an improved process for the preparation of Caspofungin acetate of a Compound of Formula (II) and Pneumocandin BO of a Compound of Formula (I), which is a key intermediate in the synthesis of Caspofungin acetate of a Compound of Formula (II).

Process&Nbsp;For The Preparation Of Purified Sacrosidase

The present invention relates to a process for the purification of Sacrosidase, which comprises elution of crude Sacrosidase solution on an anion exchange chromatography, a hydrophobic interaction chromatography, and then an ultrafiltration to obtain purified Sacrosidase.

Documents

Form DPT-3-18052021-signed
Form MGT-7-13102020_signed
List of share holders, debenture holders;-12102020
Form AOC-4(XBRL)-11092020_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-10092020
Form BEN - 2-19052020_signed
Declaration under section 90-19052020
Form DPT-3-08052020-signed
List of share holders, debenture holders;-10102019
Form MGT-7-10102019_signed
Form DIR-12-06092019_signed
Optional Attachment-(1)-06092019
Form ADT-1-05092019_signed
Copy of resolution passed by the company-05092019
Optional Attachment-(1)-05092019
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-05092019
Copy of written consent given by auditor-05092019
Form AOC-4(XBRL)-05092019_signed
Form BEN - 2-24072019_signed
Declaration under section 90-24072019
Form DPT-3-28062019
Form ADT-1-15052019_signed
Copy of written consent given by auditor-15052019
Copy of resolution passed by the company-15052019
Optional Attachment-(1)-10052019
Form DIR-12-10052019_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-10052019
Form AOC-4(XBRL)-04102018_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-03102018
Form MGT-7-24092018_signed